3D Medicines Inc. (HKG:1244)
Hong Kong · Delayed Price · Currency is HKD 3.750
+0.140 (3.88%)
Apr 17, 2026, 4:08 PM HKT
3D Medicines Revenue
In the year 2025, 3D Medicines had annual revenue of 356.09M CNY, down -20.10%. 3D Medicines had revenue of 146.92M in the half year ending December 31, 2025, a decrease of -47.97%.
Revenue
356.09M CNY
Revenue Growth
-20.10%
P/S Ratio
2.32
Revenue / Employee
1.95M CNY
Employees
183
Market Cap
920.19M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 356.09M | -89.56M | -20.10% |
| Dec 31, 2024 | 445.65M | -189.30M | -29.81% |
| Dec 31, 2023 | 634.95M | 67.56M | 11.91% |
| Dec 31, 2022 | 567.39M | 507.13M | 841.57% |
| Dec 31, 2021 | 60.26M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 586.21M |
| JW (Cayman) Therapeutics Co. | 315.65M |
| Wuhan YZY Biopharma | 85.20M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| CANbridge Pharmaceuticals | 55.62M |
| Shanghai Bio-heart Biological Technology | 50.00M |
| Brii Biosciences | 39.56M |
| Kintor Pharmaceutical | 36.37M |